ISRCTN72578000招募中未知
Protocolised follow-up of Pompe patients receiving enzyme replacement therapy on a compassionate use basis
Erasmus Medical Centre (Netherlands)0 个研究点目标入组 12 人开始时间: 2007年2月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Confirmed diagnosis of Pompe Disease
- •2. Infantile-onset:
- •2.1. Age less than one year
- •2.2. Delayed motor milestones, and/or
- •2.3. Hypertrophic cardiomyopathy
- •3. Late-onset:
- •3.1. 24 hour/day artificial ventilation
- •3.2. Wheelchair bound
- •3.3. Previously enrolled in AGLU 1202 study
排除标准
- •1. Infantile-onset:
- •1.1. congenital abnormalities
- •1.2. allergy to food and/or proteins
- •1.3. ventilator dependency
- •2. Late-onset:
- •2.1. developmental delays not explained by Pompe's Disease
- •2.2. allergies
- •2.3. severe co-morbidity
研究者
相似试验
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
进行中（未招募）
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-002440-40-DESangamo Therapeutics France SAS15
进行中（未招募）
1 期
ong term follow up for patients who have received NiCord/CordIn, stem cells from donated umbilical cord bloodthat were grown in a laboratory to expand their numberHigh risk haematological malignanciesHemoglobinopathiesMedDRA version: 18.1Level: LLTClassification code 10025316Term: Lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10040645Term: Sickle cell disease NOSSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864EUCTR2015-004813-26-ESGamida Cell Ltd76
招募中
1 期
ong-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Kidney Transplant RejectionMedDRA version: 21.1Level: LLTClassification code: 10050436Term: Prophylaxis against renal transplant rejection Class: 10042613CTIS2024-512580-31-00Sangamo Therapeutics France30
已完成
不适用
Continuation of Follow-up for Patients who were Previously Enrolled in the Clinical Study: *Open, Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity.*1000301810017998ObesityNL-OMON39582Boston Scientific Corporation17